Core Insights - The number of headquarters enterprises in Sichuan has expanded, with 31 companies recognized, bringing the total to 128 [1] - Headquarters enterprises are defined as those registered in Sichuan that conduct cross-regional operations and contribute significantly to local taxes and the economy [1] Group 1: Enterprise Distribution - The newly recognized 31 enterprises are primarily located in six cities, with a majority being private enterprises (48.4%), followed by state-owned enterprises (41.9%), foreign enterprises (6.5%), and mixed-ownership enterprises (3.2%) [2] - The main sectors represented are manufacturing (51.6%), services (32.3%), and construction (9.7%), aligning with Sichuan's modern industrial development [2] - Among these enterprises, seven have annual revenues exceeding 10 billion, and one exceeds 100 billion [2] Group 2: Classification of Headquarters - Sichuan classifies headquarters enterprises into three categories: comprehensive headquarters, functional headquarters, and growth headquarters [2] - Comprehensive headquarters must meet large enterprise standards in terms of revenue, total assets, and workforce [2] - Five functional headquarters are controlled by large enterprises from outside the province or abroad, requiring a minimum registered capital of 50 million [2] Group 3: Support Policies - Sichuan will utilize various policy tools, including fiscal, financial, technological, and talent support, to promote the development of headquarters enterprises [3] - There is an emphasis on policy coordination across provincial, municipal, and county levels to enhance the effectiveness of support measures [3]

Group 1 - The core viewpoint of the news is that Kelun Pharmaceutical's stock has shown fluctuations in price and trading volume, with a recent increase of 2.05% on December 31, reaching 29.42 yuan per share, and a total market capitalization of 47.015 billion yuan [1] - As of September 30, 2025, Kelun Pharmaceutical reported a revenue of 13.277 billion yuan, a year-on-year decrease of 20.92%, and a net profit attributable to shareholders of 1.201 billion yuan, down 51.41% year-on-year [2] - The company has a diverse revenue structure, with 48.37% from non-infusion products, 41.28% from infusion products, 7.01% from research projects, and 3.33% from other sources [1] Group 2 - Kelun Pharmaceutical has distributed a total of 6.898 billion yuan in dividends since its A-share listing, with 3.587 billion yuan distributed in the last three years [3] - The number of shareholders increased to 37,100 as of September 30, 2025, reflecting an 8.35% rise, while the average number of circulating shares per person decreased by 7.70% to 35,200 shares [2] - Major shareholders include China Europe Medical Health Mixed A, holding 40.0624 million shares, and Hong Kong Central Clearing Limited, holding 34.728 million shares, both of which have seen a reduction in their holdings compared to the previous period [3]

Core Insights - The Chengdu Million Workers Skills Competition has evolved from a competitive event to a practical empowerment platform, significantly contributing to the high-quality economic development of the Xindu District in Chengdu [2] Group 1: Event Overview - The 2025 Chengdu Million Workers Skills Competition will take place on May 22-23, featuring nearly 100 skilled workers from the Xindu High-tech Industrial Park competing in CNC milling and welding [2] - The event has been recognized as a catalyst for regional economic development, showcasing the transition from competition to practical application [2] Group 2: Competition Structure - Xindu District has successfully hosted high-level competitions for three consecutive years, including one provincial-level and one city-level competition in 2025, along with 12 district-level competitions [3] - High-level events not only enhance worker skills but also broaden corporate perspectives, facilitating a platform for enterprise collaboration [3] Group 3: Grassroots Engagement - The district has stimulated grassroots enthusiasm for hosting competitions through demonstration, financial support, and joint events, conducting five labor and skills competitions in 2025 that involved over 80 key industry chain enterprises [4] - Major companies like China Aviation Engine Corporation and Sichuan Kelun Pharmaceutical have participated in over 40 skill competitions, engaging more than 11,000 workers [4] Group 4: Communication and Participation - Xindu District emphasizes comprehensive media promotion to create an inclusive competition atmosphere, regularly holding meetings to address worker concerns and clarify competition requirements [5] - The district has actively solicited competition project ideas from various stakeholders, ensuring alignment with industry development and talent cultivation needs [5] Group 5: Focused Competitions - The district targets key industries such as aerospace, rail transportation, and food and beverage, hosting competitions that attract hundreds of skilled talents and enhance regional competitiveness [6] - The Chengdu Aviation Industry Park has seen significant growth, with 52 supporting projects and an annual output value exceeding 10 billion [6] Group 6: Industry Coverage - The district has organized competitions across various sectors, including healthcare, logistics, and public services, fostering a platform for resource sharing and skill exchange [7] Group 7: Innovation in New Fields - The district has expanded competition scope to include new employment forms, such as hosting skill competitions for couriers, showcasing advancements in intelligent delivery systems [8] - Special features like drug education zones have been integrated into competitions to enhance safety awareness among participants [8] Group 8: Results and Impact - The district has established an incentive mechanism for competitions, rewarding winners and their coaches with substantial monetary prizes based on competition levels [9] - Over the past three years, the district has produced numerous skilled workers and recognized labor models, contributing to a positive cycle of development within enterprises [9] Group 9: Future Directions - The Chengdu Million Workers Skills Competition is positioned as a catalyst for industrial development and worker growth, with plans to enhance talent cultivation platforms and improve collaboration across regions [10]

Investment Rating - The report maintains an "Outperform" rating for several companies in the pharmaceutical sector, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [5][6]. Core Insights - The report emphasizes the high prosperity in innovative drugs and continues to recommend companies with promising pipelines and performance growth in the Biopharma/Biotech sector, maintaining an "Outperform" rating for Innovent Biologics, WuXi XDC Cayman, and others [5][23]. - It highlights the performance of the A-Shares pharmaceutical sector, which underperformed the market, with the SW Pharma & Bio index falling by 0.2% while the SHCOMP rose by 1.9% [7][18]. - The report notes that the premium level of the pharmaceutical sector relative to all A-Shares is currently at a normal level of 66.7% as of December 26, 2025 [13][17]. Summary by Sections 1. Continued Recommendation for Innovative Drugs and Industry Chain - The report continues to recommend innovative drugs and the associated industry chain, highlighting the high demand and potential for revaluation in the pharmaceutical sector [5][23]. - Specific companies recommended include Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical, all rated as "Outperform" [5][6]. 2. A-Shares Pharmaceutical Sector Performance - In the fourth week of December 2025, the A-Shares pharmaceutical sector underperformed the broader market, with a decline of 0.2% compared to a 1.9% increase in the SHCOMP index [7][18]. - The best-performing sub-sectors included chemical raw materials (+2.0%) and medical equipment (+0.1%), while biological products saw a slight decline of -0.1% [9][18]. 3. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector also underperformed, with the Hang Seng Healthcare index down by 1.8% and the Hang Seng Biotechnology index down by 2.3% [18]. - In contrast, the U.S. pharmaceutical sector performed similarly to the market, with the S&P Healthcare Select Sector increasing by 1.0% [18].

Core Insights - 2025 marks a pivotal year for China's innovative pharmaceuticals, with a significant increase in international collaborations and licensing agreements, indicating a shift from a pharmaceutical giant to a stronghold in the industry [1][3] - The total amount of outbound licensing agreements exceeded $100 billion, with upfront payments reaching $8.1 billion, showcasing a transition to multi-layered cooperation models [1][3] - China's biopharmaceutical market remains the second largest globally, with innovative drugs accounting for approximately 30% of global research, reflecting a critical leap from following to competing on a global scale [1][3] Internationalization - The internationalization of China's pharmaceutical industry saw explosive growth in 2025, highlighted by a surge in business development (BD) transactions and the popularity of "A+H" listings [3][4] - The total amount of outbound licensing for innovative drugs reached over $100 billion, a 75% increase from 2024, indicating a shift from merely selling products to actively engaging in global markets [3][4] - Notable BD transactions include significant agreements between major Chinese pharmaceutical companies and international firms, such as a $12.5 billion deal between Hengrui Medicine and GSK [3][4] Innovation - In 2025, advancements in cutting-edge technologies such as antibody-drug conjugates (ADC) and dual antibodies have shown promising results in cancer treatment [7][8] - The third-generation ADC technology has become mainstream, with significant efficacy demonstrated in treating solid tumors [7] - The dual antibody sector continues to lead, with Chinese companies achieving remarkable results in clinical trials, such as a 91% improvement in progression-free survival compared to existing treatments [8] Policy Support - The policy support for innovative drugs in China has reached unprecedented levels, with a notable increase in the number of approved innovative drugs [10][11] - The National Medical Products Administration approved 69 innovative drugs in 2025, a 44% increase from the previous year, covering various therapeutic areas [10] - The payment system for innovative drugs has been significantly upgraded, enhancing accessibility and affordability for patients [10][11] Mergers and Acquisitions - The pharmaceutical sector has seen a surge in mergers and acquisitions, with over 400 transactions announced globally, totaling approximately $111 billion, marking a 50% increase from 2024 [13][14] - Domestic mergers also showed strong activity, with significant deals indicating a shift towards quality improvement and resource consolidation among leading companies [13][14] - The trend reflects a transition from scale expansion to enhancing quality and efficiency, with companies focusing on high-value clinical pipelines [14]

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The number of innovative drugs listed in China continues to grow, with domestic products accounting for approximately half of the total market share. The R&D capabilities for innovative drugs in China are also increasing, attracting global attention. Notably, the number and value of domestic innovative drug business development (BD) transactions have reached new highs, with ADC, bispecific antibodies, small nucleic acids, and CAR-T being the four key R&D directions to watch in 2026 [15][21][22] - The Chinese innovative drug market has seen a significant increase in the number of new drug applications (NDA), with domestic products making up a growing proportion. From 2017 to 2024, the number of innovative drugs listed in China rose from 41 to 92, with domestic products accounting for 50% of the total by 2024 [17][21] - The report highlights that the license-out transaction volume and total amount for Chinese companies reached $92.03 billion in the first three quarters of 2025, a 77% increase compared to the total for 2024. The upfront payment for license-out transactions has also surpassed the total financing amount in the primary market for the same period [22][25] Summary by Sections Industry Trends - The A-share pharmaceutical index has shown a year-to-date increase of 14.29%, while the Hang Seng Healthcare Index has surged by 62.29% [3][8] - The report notes that the pharmaceutical sector has experienced fluctuations, with raw materials and medical devices showing positive growth [8] R&D Progress and Company Dynamics - The report provides an overview of the R&D progress for innovative and modified drugs, including approvals and clinical applications [5] - It lists key companies to watch in various sub-sectors, including innovative drugs, research services, and medical devices, with specific recommendations for companies like Innovent Biologics, Hengrui Medicine, and WuXi AppTec [11][12] Market Insights and Regulatory Observations - The report tracks the price-to-earnings ratio of the pharmaceutical index, noting that it is currently lower than historical averages [5] - It emphasizes the importance of the regulatory environment and market dynamics in shaping the future of the pharmaceutical industry [5]

Core Viewpoint - Kelong Pharmaceutical's stock has experienced a decline, with a current price of 29.87 yuan per share and a market capitalization of 47.734 billion yuan, reflecting a challenging financial performance in recent months [1] Financial Performance - For the period from January to September 2025, Kelong Pharmaceutical reported a revenue of 13.277 billion yuan, a year-on-year decrease of 20.92%, and a net profit attributable to shareholders of 1.201 billion yuan, down 51.41% year-on-year [2] - The company's stock price has increased by 1.93% year-to-date, but has seen declines of 5.74% over the last five trading days, 13.22% over the last 20 days, and 20.27% over the last 60 days [1] Shareholder Information - As of September 30, 2025, Kelong Pharmaceutical had 37,100 shareholders, an increase of 8.35% from the previous period, with an average of 35,200 circulating shares per shareholder, a decrease of 7.70% [2] - The company has distributed a total of 6.898 billion yuan in dividends since its A-share listing, with 3.587 billion yuan distributed in the last three years [3] Institutional Holdings - Among the top ten circulating shareholders as of September 30, 2025, notable changes include a decrease in holdings by major funds such as China Europe Medical Health Mixed A and Industrial Bank Frontier Medical Stock A [3]

Group 1 - The core point of the article is that Kelun Pharmaceutical (SZ 002422) held its 10th meeting of the 8th Board of Directors on December 23, 2025, to review proposals regarding expected related party transactions for the year 2026 [1] - For the first half of 2025, the revenue composition of Kelun Pharmaceutical was as follows: 89.66% from pharmaceutical manufacturing, 7.01% from research and development projects, and 3.33% from other businesses [1] - As of the time of reporting, the market capitalization of Kelun Pharmaceutical was 49 billion yuan [1]

四川科伦药业股份有限公司 第二条 本制度适用于公司董事和高级管理人员。 第三条 公司董事、高级管理人员薪酬遵循以下原则： （一）收入水平与公司规模、经营目标与业绩匹配； （二）责、权、利对等，薪酬与岗位价值高低、履行责任义务大小相符； （三）与公司长远利益、持续健康发展的目标相符； （四）激励与约束并重、奖罚对等、按绩取酬。 董事、高级管理人员薪酬管理制度 第一章 总则 第一条 为进一步完善四川科伦药业股份有限公司（以下简称"公司"）的 治理结构，建立合理有效的企业激励约束机制，提升经营管理效益，根据《中华 人民共和国公司法》《上市公司治理准则》《上市公司章程指引》《深圳证券 交易所股票上市规则》等有关法律、行政法规、部门规章、规范性文件及《四 川科伦药业股份有限公司章程》（以下简称"《公司章程》"）的有关规定，结 合公司实际情况，制定本制度。 第二章 管理机构 第四条 公司董事、高级管理人员薪酬方案由董事会薪酬与考核委员会制定， 明确薪酬确定依据和具体构成。 董事薪酬方案由股东会审议通过，并予以披露。在董事会或者薪酬与考核委 员会对董事个人进行评价或者讨论其报酬时，该董事应当回避。 高级管理人员薪酬方案由董 ...

四川科伦药业股份有限公司 财务管理制度 第一章 总则 第一条 为适应市场经济发展的需要，规范四川科伦药业股份有限公司（以下 简称"公司"）会计确认、计量和报告行为，保证会计信息质量，使公司的会计 工作有章可循、有法可依，公允地处理会计事项，以提高公司经济效益，维护股 东权益，制定本制度。 第二条 本制度根据《中华人民共和国会计法》《企业财务通则》《会计基础 工作规范》《企业会计准则——基本准则》及后续颁布的具体准则、应用指南、 解释及其他相关规定等国家有关法律、法规、部门规章及规范性文件，结合公司 具体情况及公司对会计工作管理的要求制定。 第三条 本制度适用于公司及全资、控股子公司（以下简称"子公司"），各 子公司可根据本制度，结合自身实际情况制定实施细则。 第二章 会计核算体制 第四条 财会组织体系及机构设置和职责 1.公司负责人对本单位财务管理制度的建立健全和有效实施以及经济业务的真 实性、合法性负责；公司财务管理工作在董事会领导下由总经理组织实施，公司 财务负责人对董事会和总经理负责。 2.公司设立财务总监岗位，财务总监即公司财务负责人，负责和组织公司财务 管理工作和会计核算工作；财务总监必须按规定的任 ...